Yi M Zheng

US Patent:

7417026, Aug 26, 2008

Filed:

Aug 12, 2004

Appl. No.:

10/918328

Inventors:

David A. Williams - Cincinnati OH, US
Yi Zheng - Cincinnati OH, US

Assignee:

Children's Hospital Medical Center - Cincinnati OH

International Classification:

A61K 38/00

US Classification:

514 12

Abstract:

Improved methods and pharmaceutical compositions are provided herein for mobilizing hematopoietic progenitor cells from bone marrow into peripheral blood, comprising the administration of an effective amount of an inhibitor of GTPases, such as Rac1 and Rac2 alone or in combination. Specifically, methods are disclosed for mobilizing hematopoietic stem cells into a subject's peripheral blood. In particular, embodiments of the method involve inhibition of both Rac1 and Rac2 GTPases to increase the numbers of hematopoietic stem cells into a subject's peripheral blood of a subject. The subject's blood can be processed and used to repopulate the destroyed lymphohematopoietic system of a recipient and may in the future be utilized to repair a variety of non-hematopoietic tissues. Therefore, hematopoietic stem cells mobilized into a subject's peripheral blood by the method of the invention is useful as a source of donor cells in bone marrow transplantation for the treatment of a variety of disorders, including cancer, anemia, autoimmunity and immunodeficiency. They can also be used for increasing white blood cell survival and for chemotherapy.

US Patent:

7517890, Apr 14, 2009

Filed:

Nov 19, 2004

Appl. No.:

10/994165

Inventors:

Yi Zheng - Cincinnati OH, US
Jie Zheng - Memphis TN, US
Yuan Gao - Port Jefferson NY, US
John B. Dickerson - Memphis TN, US

Assignee:

Children's Hospital Medical Center - Cincinnati OH
St. Jude Children's Research Hospital - Memphis TN
Girindus America, Inc. - Cincinnati OH

International Classification:

A61K 31/506

US Classification:

514275

Abstract:

The preferred embodiments generally relate to methods and compositions that affect the GTP-binding activity of members of the Rho family GTPases, preferably Rac (Rac1, Rac2 and/or Rac3), such compositions include compounds that modulate the GTP/GDP exchange activity, along with uses for the compounds including screening for compounds which recognize Rac GTPase, and methods of treating pathological conditions associated or related to a Rho family GTPase, including Rac. The preferred embodiments also relate to methods of using such compounds, or derivatives thereof, e. g. , in therapeutics, diagnostics, and as research tools.

US Patent:

7612080, Nov 3, 2009

Filed:

Nov 18, 2005

Appl. No.:

11/283556

Inventors:

Yi Zheng - Cincinnati OH, US
Huzoor Akbar - Athens OH, US
David A. Williams - Cincinnati OH, US
Wieslaw Adam Mazur - Mason OH, US

Assignee:

Cincinnati Children's Hospital Medical Center - Cincinnati OH

International Classification:

A61K 31/506

US Classification:

514275

Abstract:

The preferred embodiments generally relate to methods and compositions that affect the GTP-binding activity of members of the Rho family GTPases, preferably Rac (Rac1, Rac2 and/or Rac3), such compositions include compounds that modulate the GTP/GDP exchange activity, along with uses for the compounds including screening for compounds which recognize Rac GTPase, and methods of treating pathological conditions associated or related to a Rho family GTPase, including Rac. The preferred embodiments also relate to methods of using such compounds, or derivatives thereof, e. g. , in therapeutics, diagnostics, and as research tools.

US Patent:

7826982, Nov 2, 2010

Filed:

Jul 31, 2006

Appl. No.:

11/496959

Inventors:

Yi Zheng - Cincinnati OH, US
Nicolas Nassar - Coram NY, US
Karlheinz R. Skowronek - Huntington Station NY, US

Assignee:

Children's Hospital Medical Center - Cincinnati OH
The Research Foundation of State University of New York - Stony Brook NY

International Classification:

G01N 31/00
G06G 7/58

US Classification:

702 27, 703 11

Abstract:

The preferred embodiments generally relate to methods and compositions that affect the GTP-binding activity of members of the Rho family GTPases, preferably Rac (Rac1, Rac2 and/or Rac3), such compositions include compounds that modulate the GTP/GDP exchange activity, along with uses for the compounds including screening for compounds which recognize Rac GTPase, and methods of treating pathological conditions associated or related to a Rho family GTPase, including Rac. The preferred embodiments also relate to methods of using such compounds, or derivatives thereof, e. g. , in therapeutics, diagnostics, and as research tools.

US Patent:

7915384, Mar 29, 2011

Filed:

Jan 5, 2009

Appl. No.:

12/348762

Inventors:

Yi Zheng - Cincinnati OH, US
David A. Williams - Cincinnati OH, US

Assignee:

Children's Hospital Medical Center - Cincinnati OH

International Classification:

C07K 14/00
A01N 37/18

US Classification:

530350, 514 2

Abstract:

Chimeric peptides or fusion proteins are disclosed that include a RhoGAP activity domain and at least one specificity domain that targets a specific Rho protein. The fusion proteins can be used to inhibit any GTPase activity within a cell. The fusion proteins are particularly advantageous for the treatment of cancer. The present invention generally relates to chimeric peptides capable of regulating GTPases, and more particularly, to methods of targeting individual GTPases by using GTPase-activating proteins. Such proteins may be used for the treatment of cancers and other GTPase-related diseases. This invention relates to nucleic acid molecules and the encoded GTPase activating proteins, and variants thereof, and to the use of these molecules in the characterization, diagnosis, prevention, and treatment of cell signaling, immune, and cell proliferative disorders, particularly cancer. Disclosed herein are compounds and methods for regulating transcription of a selected gene.

US Patent:

8242246, Aug 14, 2012

Filed:

Feb 28, 2011

Appl. No.:

13/036964

Inventors:

Yi Zheng - Cincinnati OH, US
David A. Williams - Cincinnati OH, US

Assignee:

Children's Hospital Medical Center - Cincinnati OH

International Classification:

C07K 14/00
A61K 38/00

US Classification:

530350, 514 11

Abstract:

Chimeric peptides or fusion proteins are disclosed that include a RhoGAP activity domain and at least one specificity domain that targets a specific Rho protein. The fusion proteins can be used to inhibit any GTPase activity within a cell. The fusion proteins are particularly advantageous for the treatment of cancer. The present invention generally relates to chimeric peptides capable of regulating GTPases, and more particularly, to methods of targeting individual GTPases by using GTPase-activating proteins. Such proteins may be used for the treatment of cancers and other GTPase-related diseases. This invention relates to nucleic acid molecules and the encoded GTPase activating proteins, and variants thereof, and to the use of these molecules in the characterization, diagnosis, prevention, and treatment of cell signaling, immune, and cell proliferative disorders, particularly cancer. Disclosed herein are compounds and methods for regulating transcription of a selected gene.

US Patent:

8383124, Feb 26, 2013

Filed:

Mar 12, 2009

Appl. No.:

12/922026

Inventors:

Yi Zheng - Cincinnati OH, US

Assignee:

Children's Hospital Medical Center - Cincinnati OH

International Classification:

A61K 39/00
A01N 25/00

US Classification:

4241841, 514885

Abstract:

Methods, processes, uses, and pharmaceutical compositions are provided herein for mobilizing hematopoietic progenitor cells and/or cancer stem cells from bone marrow into peripheral blood, comprising the administration of an effective amount of an inhibitor of GTPases, such as a Cdc-42 specific inhibitor alone or in combination with one or more additional agents. Specifically, methods are disclosed for mobilizing hematopoietic stem cells into a subject's peripheral blood. In particular, embodiments of the method involve specific inhibition of the Cdc42 GTPase to increase the numbers of hematopoietic stem cells into a subject's peripheral blood of a subject.

US Patent:

20050069553, Mar 31, 2005

Filed:

Aug 12, 2004

Appl. No.:

10/918648

Inventors:

Yi Zheng - Cincinnati OH, US
David Williams - Cincinnati OH, US

International Classification:

A61K039/395
C07K016/44

US Classification:

424178100, 530387300

Abstract:

Chimeric peptides or fusion proteins are disclosed that include a RhoGAP activity domain and at least one specificity domain that targets a specific Rho protein. The fusion proteins can be used to inhibit any GTPase activity within a cell. The fusion proteins are particularly advantageous for the treatment of cancer. The present invention generally relates to The present invention generally relates to chimeric peptides capable of regulating GTPases, and more particularly, to methods of targeting individual GTPases by using GTPase-activating proteins. Such proteins may be used for the treatment of cancers and other GTPase-related diseases. This invention relates to nucleic acid molecules and the encoded GTPase activating proteins, and variants thereof, and to the use of these molecules in the characterization, diagnosis, prevention, and treatment of cell signaling, immune, and cell proliferative disorders, particularly cancer. Disclosed herein are compounds and methods for regulating transcription of a selected gene. Methods are provided for constructing and for using such compounds to regulate transcription of a selected gene.